Get Magazines for free

Categories

10000 to 4crs in 18 months 1000rs to 50crs 300% returns 75% promoter holdings A 50 bagger A sureshot 5 bagger Analysis Another fraud? Auto ancillaries Bank sector Blind sell Brand plays Broking Bse Nse Buy calls cements Ceramics/tiles Counters I don't like Debt free businesses Delisting candidates demerger bets Disclosure- I own them Domestic consumption plays E-Commerce pick Education Exit at rallies Famous analysts Famous stocks FMCG Footwear future multibaggers Gems andJewellery Hidden gems High conviction ideas High dividend plays High potential small caps High ROE stocks Holding companies Hotel sector How they looted you.. Indian stock market Infrastructure sector Interesting Microcaps IT KPO Landbank plays largecap ideas Less than 5 PE stocks Liquor Logistics Market lessons Market outlook for 2013 and 2014 Market underperformers Meeting with the CEO Metals Monopoly businesses My 5 baggers My Favourite counters My paid stock recommendations My stock picking techniques nse bse tips Oil exploration Operator calls Paints Penny stock outlook penny stock updates Pharma sector Poultry stocks PSU Publicity freaks Real estate Renewable energy plays Safe bets Sell recommendations Share market Live shipping stocks short term call SOTP plays stock tips stock under 10rs Stocks to watch out for Strong bonus candidates Takeover candidates TATA product tea Textiles The 13 bagger The 45 bagger Trading companies Transformers Turnaround bets Tyres Uncertain/Risky business models Unique businesses

Search This Blog(Over 800 companies covered in the blog).

Please note

Note: The artciles are not research reports but assimilation of information available on public domain and it should not be treated as a research report.

Registration status with SEBI: I am not registered with SEBI under the (Research Analyst) regulations 2014 and as per clarifications provided by SEBI: “Any person who makes recommendation or offers an opinion concerning securities or public offers only through public media is not required to obtain registration as research analyst under RA Regulations”

Disclosure: It is safe to assume that I might have the dkiscussed companies in my portfolio and hence my point of view can be biased.Readers should consult registered consultants before making any investments
.

Archives : Old artciles

Sunday, December 13, 2009

Astec Lifesciences Ltd:Buy/sell/hold,growth prospects and recomendation,news and results,target price and analysis

Scripscan:Astec Lifesciences Ltd
Code:533138
cmp:90

Story:Astec Lifesciences (Astec) has been promoted by Ashok Hiremath and Dr P L Tiwari. Ashok Hiremath has dissociated from his brother Jai Hiremath, who is a promoter of listed company Hikal. Astec is predominantly an agrochemicals player and operates in an extensively competitive agrochemicals and pharmaceutical industry, with major focus on the manufacture and sale of intermediates, active ingredients and formulations in the off-patent–proprietary category. Active ingredients are sold to crop protection formulators, whereas intermediates are supplied to technical grade product manufacturers and formulations are sold in bulk quantities to companies engaged in retail marketing. Astec's three manufacturing facilities, located at Dombivli (one unit) and Mahad (two units) in Maharashtra, have a total installed capacity of 2,800 tonnes. These facilities have been granted ISO 9001:2000 certificate of assessment by International Standards Certification Pty Limited, Australia, for "Design, Development, Manufacture and Supply of Organic Chemicals and Intermediates for Pharmaceutical and Agrochemical Industry".Hexaconazole, Tebuconazole, Metalaxyl and Propiconazole are some of the key products of Astec in the agrochemical segment. These are generally used in crop protection. Dicap, one of the company's key pharmaceutical intermediate products, which is used in manufacture of antifungal agents. Triazole fungicides, which includes Hexaconazole, Tebuconazole, and Propiconazole is one of the company's major product in the agrochemical segment, and has contributed 65.81% of the total sales, whereas Dicap, a key product in pharmaceutical segment, contributed 14.14% in 2008-09. Besides enjoying a good pie of the domestic market, the company has been able to successfully venture into the international market as well, exporting its produce to countries like South Africa, Europe, USA, West Asia, East Asia, Japan and South America. The company plans to enter into long-term supply contracts with the buyers in these countries in order to scale up exports.Astec's concerted effort to identify contract manufacturing as one of the options to maintain growth and profitability and also to undertake contract research and manufacturing (CRAMS) business will enable a predictable pattern of demand going ahead.To further diversify and widen the product range besides increasing the existing capacity, Astec plans to expand its existing manufacturing facilities at Mahad at an estimated cost of Rs 32.56 crore. The company plans to add nearly 1,150 tonnes of agrochemicals and pharma intermediates to its existing capacity of 2800 metric tonnes. It further plans to expand its research & development centre at Dombivli at an estimated cost of Rs 2.55 crore by expanding its bench scale capabilities, improve analytical capabilities and expand its pilot plant. The proposed expansion will enable the company to carry out research on more complex molecules and to undertake contract research activities. In addition to this, Astec also plans to incur Rs 3.76 crore for both domestic and international product registration. All the capital expenditure would be financed from the proceeds of the initial public offering (IPO) and internal cash accruals.Has six diverse products comprising a mix of high volume-medium margin and low volume-high margin category, comprising different kinds of active ingredients, intermediates and formulations catering to the needs of a wide range of customers like agrochemicals manufacturers, pharmaceutical applications and also in manufacturing shampoos and disinfectants.Has a research & development (R&D) facility at Dombivli recognised by the Department of Science and Industrial Research, which has been able to develop processes for various new products like Tebuconazole, Propiconozole and Metalaxyl. Has existing 43 registrations in 20 countries where local firms/parties have obtained the registration on the basis of being the approved source of supply and three registrations in its own name, two in Australia and one in Vietnam. In addition to overseas registrations, has 69 CIB registrations for various products in the Indian market. Has a good mix of domestic and international sales mix with the exports and deemed exports together comprising 29.52% of the total revenue in the previous fiscal.Has managed to consistency achieve a higher capacity utilization level. The average capacity utilization was 85% in the past three years.The company is trading at nearly a PE of 15 FY 2009 EPS of Rs 6.3. Near comparable companies Sabero Organics and Meghmani Organics are trading at a trailing 12- month PE of 4.4 and 6.1, respectively. Composite average TTM P/E for small/medium agrochemical companies is around 6.Looks overvalued though any stunning numbers in the coming quarters can make it propel bigtime.One can take an exposure at 65 levels for decent capital appreciation in the longer run.

Important Disclaimer&Privacy policy

This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: arunsharemarket@gmail.com Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.
 
x

Subscription to Arunthestocksguru

Enter your email address:

Delivered by FeedBurner